Delaware
|
000-16375
|
94-3018487
|
||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
[x]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
99.1
|
Press Release: TotipotentRX and ThermoGenesis to Present Clinical Data at the AABB Conference.
|
|
99.2
|
Press Release: TotipotentRX & ThermoGenesis Case Study Demonstrates Autologous Stem Cell Product Safely Treats Primary Heart Attach in 60 Minute Clinical Procedure; Initial data from AMIRST combination product therapy 24 month safety case study released.
|
|
99.3
|
Clinical Case Report: Safety Study of Autologous Bone Marrow Concentrate Enriched in Progenitor Cells (BMCEPC) as an Adjuvant, in the Treatment of Acute Myocardial Infarction.
|
THERMOGENESIS CORP.,
|
|||
a Delaware Corporation
|
|||
/s/ Dan T. Bessey | |||
Dan T. Bessey
|
|||
Chief Financial Officer
|
|||